Cargando…
Ticagrelor vs. Clopidogrel in Acute Coronary Syndrome Patients With Chronic Kidney Disease After New-Generation Drug-Eluting Stent Implantation
Background: The impact of ticagrelor-based dual antiplatelet therapy (DAPT) on acute coronary syndrome (ACS) in patients with chronic kidney disease (CKD) remains unclear. Methods: Data on a total of 1,067 ACS patients with CKD including end-stage renal disease (ESRD) who underwent new-generation dr...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8785207/ https://www.ncbi.nlm.nih.gov/pubmed/35083294 http://dx.doi.org/10.3389/fcvm.2021.707722 |
_version_ | 1784638914685829120 |
---|---|
author | Roh, Ji Woong Lee, Seung-Jun Kim, Byeong-Keuk Hong, Sung-Jin Kim, Hee-Yeol Ahn, Chul-Min Cho, Deok-Kyu Kim, Jung-Sun Ko, Young-Guk Choi, Donghoon Hong, Myeong-Ki Jang, Yangsoo |
author_facet | Roh, Ji Woong Lee, Seung-Jun Kim, Byeong-Keuk Hong, Sung-Jin Kim, Hee-Yeol Ahn, Chul-Min Cho, Deok-Kyu Kim, Jung-Sun Ko, Young-Guk Choi, Donghoon Hong, Myeong-Ki Jang, Yangsoo |
author_sort | Roh, Ji Woong |
collection | PubMed |
description | Background: The impact of ticagrelor-based dual antiplatelet therapy (DAPT) on acute coronary syndrome (ACS) in patients with chronic kidney disease (CKD) remains unclear. Methods: Data on a total of 1,067 ACS patients with CKD including end-stage renal disease (ESRD) who underwent new-generation drug-eluting stent implantation were extracted from a multicenter registry. This study aimed to compare outcomes of patients treated with ticagrelor- (n = 449) and those treated with clopidogrel-based (n = 618) DAPT. Outcomes of interest included major adverse cardiac and cerebrovascular events (MACCEs) and bleeding (Bleeding Academic Research Consortium grade 3 or 5) at 12 months. Propensity-score matching (346 pairs) analysis was performed. Results: The patients with ESRD showed the highest MACCE and bleeding rates (P < 0.001). There was no difference in the rate of MACCEs between the treatment groups (7.8% vs. 8.4%; hazard ratio [HR] = 0.95, 95% confidence interval [CI] = 0.56–1.61, P = 0.855); however, a trend toward an increased bleeding rate was observed in the ticagrelor-based DAPT group (6.8% vs. 3.8%, HR = 1.84, 95% CI = 0.93–3.63, P = 0.079). Among patients with CKD stage III/IV but without ESRD (277 pairs), the ticagrelor-based DAPT group showed a reduced MACCE rate (3.6% vs. 8.7%, HR = 0.41, 95% CI = 0.19–0.86, P = 0.018) and a similar bleeding rate (5.1% vs. 3.2%, HR = 1.61, 95% CI = 0.70–3.71, P = 0.267), compared with those of the clopidogrel-based DAPT group. Conclusion: The effects of ticagrelor-based DAPT on ischemic and bleeding outcomes of ACS patients with CKD varied according to CKD stage; in ACS patients with CKD without ESRD, ticagrelor-based DAPT reduced MACCE risk without increasing bleeding risks, relative to those observed with clopidogrel-based DAPT. |
format | Online Article Text |
id | pubmed-8785207 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87852072022-01-25 Ticagrelor vs. Clopidogrel in Acute Coronary Syndrome Patients With Chronic Kidney Disease After New-Generation Drug-Eluting Stent Implantation Roh, Ji Woong Lee, Seung-Jun Kim, Byeong-Keuk Hong, Sung-Jin Kim, Hee-Yeol Ahn, Chul-Min Cho, Deok-Kyu Kim, Jung-Sun Ko, Young-Guk Choi, Donghoon Hong, Myeong-Ki Jang, Yangsoo Front Cardiovasc Med Cardiovascular Medicine Background: The impact of ticagrelor-based dual antiplatelet therapy (DAPT) on acute coronary syndrome (ACS) in patients with chronic kidney disease (CKD) remains unclear. Methods: Data on a total of 1,067 ACS patients with CKD including end-stage renal disease (ESRD) who underwent new-generation drug-eluting stent implantation were extracted from a multicenter registry. This study aimed to compare outcomes of patients treated with ticagrelor- (n = 449) and those treated with clopidogrel-based (n = 618) DAPT. Outcomes of interest included major adverse cardiac and cerebrovascular events (MACCEs) and bleeding (Bleeding Academic Research Consortium grade 3 or 5) at 12 months. Propensity-score matching (346 pairs) analysis was performed. Results: The patients with ESRD showed the highest MACCE and bleeding rates (P < 0.001). There was no difference in the rate of MACCEs between the treatment groups (7.8% vs. 8.4%; hazard ratio [HR] = 0.95, 95% confidence interval [CI] = 0.56–1.61, P = 0.855); however, a trend toward an increased bleeding rate was observed in the ticagrelor-based DAPT group (6.8% vs. 3.8%, HR = 1.84, 95% CI = 0.93–3.63, P = 0.079). Among patients with CKD stage III/IV but without ESRD (277 pairs), the ticagrelor-based DAPT group showed a reduced MACCE rate (3.6% vs. 8.7%, HR = 0.41, 95% CI = 0.19–0.86, P = 0.018) and a similar bleeding rate (5.1% vs. 3.2%, HR = 1.61, 95% CI = 0.70–3.71, P = 0.267), compared with those of the clopidogrel-based DAPT group. Conclusion: The effects of ticagrelor-based DAPT on ischemic and bleeding outcomes of ACS patients with CKD varied according to CKD stage; in ACS patients with CKD without ESRD, ticagrelor-based DAPT reduced MACCE risk without increasing bleeding risks, relative to those observed with clopidogrel-based DAPT. Frontiers Media S.A. 2022-01-10 /pmc/articles/PMC8785207/ /pubmed/35083294 http://dx.doi.org/10.3389/fcvm.2021.707722 Text en Copyright © 2022 Roh, Lee, Kim, Hong, Kim, Ahn, Cho, Kim, Ko, Choi, Hong and Jang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cardiovascular Medicine Roh, Ji Woong Lee, Seung-Jun Kim, Byeong-Keuk Hong, Sung-Jin Kim, Hee-Yeol Ahn, Chul-Min Cho, Deok-Kyu Kim, Jung-Sun Ko, Young-Guk Choi, Donghoon Hong, Myeong-Ki Jang, Yangsoo Ticagrelor vs. Clopidogrel in Acute Coronary Syndrome Patients With Chronic Kidney Disease After New-Generation Drug-Eluting Stent Implantation |
title | Ticagrelor vs. Clopidogrel in Acute Coronary Syndrome Patients With Chronic Kidney Disease After New-Generation Drug-Eluting Stent Implantation |
title_full | Ticagrelor vs. Clopidogrel in Acute Coronary Syndrome Patients With Chronic Kidney Disease After New-Generation Drug-Eluting Stent Implantation |
title_fullStr | Ticagrelor vs. Clopidogrel in Acute Coronary Syndrome Patients With Chronic Kidney Disease After New-Generation Drug-Eluting Stent Implantation |
title_full_unstemmed | Ticagrelor vs. Clopidogrel in Acute Coronary Syndrome Patients With Chronic Kidney Disease After New-Generation Drug-Eluting Stent Implantation |
title_short | Ticagrelor vs. Clopidogrel in Acute Coronary Syndrome Patients With Chronic Kidney Disease After New-Generation Drug-Eluting Stent Implantation |
title_sort | ticagrelor vs. clopidogrel in acute coronary syndrome patients with chronic kidney disease after new-generation drug-eluting stent implantation |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8785207/ https://www.ncbi.nlm.nih.gov/pubmed/35083294 http://dx.doi.org/10.3389/fcvm.2021.707722 |
work_keys_str_mv | AT rohjiwoong ticagrelorvsclopidogrelinacutecoronarysyndromepatientswithchronickidneydiseaseafternewgenerationdrugelutingstentimplantation AT leeseungjun ticagrelorvsclopidogrelinacutecoronarysyndromepatientswithchronickidneydiseaseafternewgenerationdrugelutingstentimplantation AT kimbyeongkeuk ticagrelorvsclopidogrelinacutecoronarysyndromepatientswithchronickidneydiseaseafternewgenerationdrugelutingstentimplantation AT hongsungjin ticagrelorvsclopidogrelinacutecoronarysyndromepatientswithchronickidneydiseaseafternewgenerationdrugelutingstentimplantation AT kimheeyeol ticagrelorvsclopidogrelinacutecoronarysyndromepatientswithchronickidneydiseaseafternewgenerationdrugelutingstentimplantation AT ahnchulmin ticagrelorvsclopidogrelinacutecoronarysyndromepatientswithchronickidneydiseaseafternewgenerationdrugelutingstentimplantation AT chodeokkyu ticagrelorvsclopidogrelinacutecoronarysyndromepatientswithchronickidneydiseaseafternewgenerationdrugelutingstentimplantation AT kimjungsun ticagrelorvsclopidogrelinacutecoronarysyndromepatientswithchronickidneydiseaseafternewgenerationdrugelutingstentimplantation AT koyoungguk ticagrelorvsclopidogrelinacutecoronarysyndromepatientswithchronickidneydiseaseafternewgenerationdrugelutingstentimplantation AT choidonghoon ticagrelorvsclopidogrelinacutecoronarysyndromepatientswithchronickidneydiseaseafternewgenerationdrugelutingstentimplantation AT hongmyeongki ticagrelorvsclopidogrelinacutecoronarysyndromepatientswithchronickidneydiseaseafternewgenerationdrugelutingstentimplantation AT jangyangsoo ticagrelorvsclopidogrelinacutecoronarysyndromepatientswithchronickidneydiseaseafternewgenerationdrugelutingstentimplantation |